Best GLP-1 for Men

Summary: Tirzepatide gives men the largest average weight loss in head-to-head data, semaglutide owns the cardiovascular outcomes evidence, and access route matters more than any sex-specific marketing claim.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer for most men: tirzepatide (Zepbound) for the largest weight loss, semaglutide (Wegovy) if cardiovascular risk reduction is the priority, and the manufacturer direct programs (LillyDirect, NovoCare) if cash price is what gates the decision. There is no male-only GLP-1, no testosterone-formulated variant, no "men's" dosing schedule. The medications are identical across sexes. What changes is the conversation around muscle preservation, cardiovascular risk, and how access actually plays out for adult men paying for this themselves.

Below is what the trial data says about men specifically, how tirzepatide and semaglutide compare head to head, and the matrix for matching the right drug to the right reason.

What the trial data actually shows about men

Sex was reported as a subgroup variable in every pivotal GLP-1 obesity trial. The pattern is consistent: men and women lose similar percentages of body weight, but the absolute kilogram numbers run higher in men because men start heavier.

In SURMOUNT-1, the trial that supported Zepbound's approval for chronic weight management, tirzepatide produced mean weight loss of around 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks ^[1]. The sex subgroup analysis showed comparable percent reductions for men and women at each dose. STEP 1, the registration trial for Wegovy, ran semaglutide 2.4 mg to a mean weight loss of 14.9% versus 2.4% on placebo at 68 weeks, again with sex-stratified results that placed male patients within a few percentage points of female patients ^[2].

That matters because the marketing claim that GLP-1s "work better for women" is often pulled from real-world telehealth aggregator data, not from randomized trials. In the controlled setting where adherence and titration are managed, the gap closes. The percent reductions are similar. Men just have more starting mass, so the pound number on the scale moves further.

Tirzepatide vs semaglutide head to head: SURMOUNT-5

SURMOUNT-5 settled the head-to-head question. Published in the New England Journal of Medicine in 2025, the trial randomized 751 adults with obesity (without diabetes) to maximum tolerated doses of tirzepatide or semaglutide for 72 weeks ^[3]. Tirzepatide produced a mean weight reduction of 20.2% versus 13.7% for semaglutide. Tirzepatide also produced a larger reduction in waist circumference (18.4 cm versus 13.0 cm). The trial enrolled both sexes, and the relative advantage of tirzepatide held across the male subgroup.

For a man choosing between the two purely on the size of the weight loss number, tirzepatide wins. Both are weekly subcutaneous injections. Both titrate over months. The side effect profiles overlap, with GI symptoms (nausea, constipation, occasional vomiting) being the dominant complaint for both molecules during dose escalation.

The semaglutide arm is not weak. A 13.7% loss is clinically meaningful and crosses the threshold for measurable cardiometabolic improvement. But if a man's stated goal is the biggest fat reduction the regulated market supports, tirzepatide is the answer the SURMOUNT-5 numbers point to.

Why men ask different questions: testosterone, muscle, cardiovascular risk

The drug is the same. The follow-on questions are different.

Testosterone and the obesity loop

Obesity suppresses testosterone. Adipose tissue expresses aromatase, the enzyme that converts testosterone to estradiol, so a heavier man runs lower free testosterone for any given gonadal output. Losing substantial weight typically raises measured testosterone. Multiple observational analyses of men on GLP-1 therapy have shown serum testosterone moving upward as weight comes down, with the magnitude tracking the magnitude of the weight loss. The mechanism is the weight loss itself, not a direct hormonal action of the drug. A man on tirzepatide losing 20% of body weight should expect his testosterone trajectory to follow his waist size, not because the drug is androgenic, but because the underlying suppression is fat-driven.

That said, GLP-1s are not testosterone therapy. If a man's labs already show clinical hypogonadism, weight loss alone may not normalize him, and the standard of care for hypogonadism (an endocrinology referral, exogenous testosterone, or treatment of the underlying cause) is separate from the GLP-1 conversation.

Muscle preservation

Aggressive weight loss of any kind, surgical, dietary, or pharmacologic, drops lean mass alongside fat mass. The lean component typically runs 25 to 40% of total loss. For a man losing 50 pounds on tirzepatide, that means roughly 12 to 20 pounds of lean tissue is on the table if nothing is done to defend it. Two interventions consistently flatten that curve: resistance training (two to four sessions per week of progressive loading) and adequate protein intake (typically 1.2 to 1.6 grams per kilogram of goal body weight). Neither is GLP-1 specific. Both apply to any rapid-loss protocol, and both are widely under-discussed in telehealth onboarding.

Cardiovascular risk reduction

This is where semaglutide carries a unique claim. SELECT, published in NEJM in 2023, randomized over 17,600 adults with established cardiovascular disease and overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo ^[4]. The trial reported a 20% relative reduction in major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, nonfatal stroke). Over 70% of the SELECT cohort was male, which puts the result on solid footing for the population of men with prior cardiovascular events deciding whether semaglutide is worth the cost.

Tirzepatide has cardiovascular outcomes trials underway (SURPASS-CVOT, SURMOUNT-MMO) but does not yet have a finalized MACE-reduction label on the semaglutide scale. So for a man in his late 40s or 50s with established coronary disease or a prior infarct, the data trail still points to semaglutide for the cardioprotection question even though tirzepatide produces more weight loss in head-to-head trials.

The recommendation matrix

Two variables drive the choice: what you are trying to achieve, and what you can pay for or get covered.

Cost and access in 2026

For men paying cash, the price ladder runs roughly like this. Brand-name retail without insurance sits at around $1,000 to $1,400 per month for Wegovy or Zepbound pens. Manufacturer direct vial programs (LillyDirect for Zepbound, NovoCare for Wegovy) bring that into the $349 to $499 range for single-dose vials at most strengths. Compounded semaglutide and tirzepatide through telehealth platforms run $179 to $399 per month depending on dose and program, but the regulatory standing is different and supply has tightened since both drugs came off the FDA shortage list.

If insurance covers GLP-1s for weight management, copays with a manufacturer savings card can drop to $25 a month. Roughly one in five large employer plans covered GLP-1s for weight loss in 2025, and the share is rising slowly. Coverage odds improve when there is a comorbid indication on file: type 2 diabetes (covered almost universally), established cardiovascular disease (Wegovy now carries a cardiovascular risk reduction indication), or MASH (also now on the Wegovy label).

For a man with type 2 diabetes, insurance coverage is the default rather than the exception, and Mounjaro or Ozempic at copay pricing will almost always undercut any cash-pay weight-loss program.

What to ignore in the "best GLP-1 for men" pitch

A few claims show up repeatedly in male-targeted GLP-1 marketing that are not supported by trial data.

Testosterone-boosting GLP-1 formulations do not exist. No FDA-approved GLP-1 is formulated with testosterone, DHEA, or any androgen. Programs that bundle "GLP-1 plus TRT" are stacking two separate prescriptions, which can be clinically appropriate if labs justify TRT, but the GLP-1 is the same molecule everyone else gets.

Male-specific dosing schedules are not a thing. The titration schedule (Zepbound 2.5 mg for four weeks, step up by 2.5 mg every four weeks; Wegovy 0.25 mg for four weeks, escalating to 2.4 mg over 16 weeks) is set by the FDA label and is sex-neutral ^[5].

Higher starting doses for men are a red flag. The titration exists for tolerance, not for sex. A program that starts a man at 5 mg of tirzepatide or 0.5 mg of semaglutide in week one is putting him at much higher risk of severe GI side effects without any efficacy gain, because therapeutic effect is built over the titration period.

How to actually decide in five minutes

Ask three questions, in order.

1. Do you have type 2 diabetes or established heart disease? If yes, semaglutide (Ozempic if diabetic, Wegovy if not) is the default because of SELECT and the broader cardiovascular outcomes story. Insurance coverage will usually be better here too.
2. Is your only goal weight loss, and you want the biggest number? Tirzepatide via Zepbound. SURMOUNT-5 is the data point that justifies that pick.
3. Is cost the gating issue? Skip retail. Go to LillyDirect for Zepbound single-dose vials or NovoCare for Wegovy. If those are still out of reach, compounded options exist but come with a different regulatory and quality profile that has to be evaluated separately.

That sequence gets most adult men to the right drug in under ten minutes of decision time. The execution (titration, side effect management, lab monitoring, lifestyle support) is where the real work sits, and that is the same work regardless of which molecule you end up on.

Common questions men ask before starting

Is there a GLP-1 specifically designed for men?

No. Zepbound, Wegovy, Ozempic, Mounjaro, and Saxenda are sex-neutral. The medications, dosing schedules, and FDA labels do not change based on sex.

Do men lose more weight on GLP-1s than women?

In randomized trials like SURMOUNT-1 and STEP 1, men and women lose similar percentages of body weight. Men typically lose more absolute pounds because they start heavier.

Which GLP-1 produces the most weight loss in men?

Tirzepatide (Zepbound). SURMOUNT-5 showed tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide at 72 weeks, with the advantage holding in the male subgroup.

Does GLP-1 use affect erectile dysfunction or testosterone?

Substantial weight loss generally raises serum testosterone in men with obesity because adipose tissue suppresses testosterone via aromatase. ED outcomes track the underlying metabolic improvement rather than a direct drug effect.

Which GLP-1 is best for men with heart disease?

Semaglutide (Wegovy or Ozempic). The SELECT trial showed a 20% reduction in major adverse cardiovascular events in adults with established cardiovascular disease, with men making up most of the cohort.

How do I preserve muscle while losing fat on a GLP-1?

Resistance train two to four times per week and target 1.2 to 1.6 grams of protein per kilogram of goal body weight daily. Without those inputs, 25 to 40% of weight lost typically comes from lean tissue.

Are GLP-1s safe for young adult men in their 20s?

GLP-1 weight-loss approvals apply to adults age 18 and up who meet BMI criteria. Liraglutide and semaglutide also carry pediatric approvals down to age 12 for obesity. Adults 18 to 25 with qualifying BMI can access the same therapies as older adults.

Can men in their 30s and 40s use GLP-1s long term?

Yes. Trials including SURMOUNT-1, STEP 1, SELECT, and SURMOUNT-5 have followed adults on continuous therapy for 68 to 176 weeks. The current evidence supports indefinite use for chronic weight management when the drug is tolerated and producing benefit.

What is the cheapest way to get a real GLP-1 as a man paying cash?

Manufacturer direct programs. LillyDirect sells Zepbound single-dose vials and NovoCare sells Wegovy vials at the lowest verified retail price for the FDA-approved product, typically several hundred dollars below pen retail.

Can I take a GLP-1 if I have a CDL, DOT physical, or FAA medical certification?

GLP-1 use is not itself disqualifying for most CDL or commercial driver medical exams. The underlying conditions (diabetes management, recent hypoglycemia) and any side effects affecting alertness are what the examiner evaluates. FAA medical certification requires disclosure and case-by-case AME review.

Bottom line

For most men in 2026 picking a GLP-1 from scratch, the answer is tirzepatide (Zepbound) for the largest weight loss, semaglutide (Wegovy or Ozempic) for cardioprotection or insurance-friendly pricing through a diabetes diagnosis, and the manufacturer direct programs (LillyDirect, NovoCare) when cash is the constraint. The "best for men" framing is mostly marketing. The data that matters is the same data women see, applied to a body composition starting point that runs heavier and a downstream conversation about muscle, testosterone, and cardiovascular risk that women are not always asked the same way.